医学
胰高血糖素样肽1受体
内科学
安慰剂
兴奋剂
心脏病学
舒张期
内分泌学
随机对照试验
胰高血糖素样肽-1
期限(时间)
2型糖尿病
糖尿病
受体
血压
物理
病理
量子力学
替代医学
作者
Annemie Stege Bojer,Martin Heyn Sørensen,Jenny Bjerre,Peter Gæde,Niels Vejlstrup,Per Lav Madsen
摘要
Abstract Aim To investigate if short‐term treatment with liraglutide, a glucagon‐like peptide‐1 receptor agonist, improves left ventricular diastolic function. Materials and Methods An investigator‐initiated, double‐blind, randomized, placebo‐controlled trial on the effect of 18 weeks of treatment with liraglutide on diastolic function was assessed in patients with type 2 diabetes with signs of diastolic dysfunction (echo‐Doppler determined E/e' ≥ 9 and/or lateral e' ≤ 10 cm/s). Primary outcomes were improved left ventricle filling (the early peak filling rate [ePFR]) and left atrium ease of emptying (the passive emptying fraction [LA PEF ]), assessed by cardiac magnetic resonance imaging at rest and during chronotropic stress. Secondary outcomes included left ventricular and left atrial volumes and systolic function, measures of aortic stiffness and echocardiographic diastolic variables. Results Forty patients were randomized to liraglutide subcutaneously 1.8 mg/day (n = 20) or placebo (n = 20). Liraglutide reduced HbA1c (−0.47%, 95% CI [−0.88% to −0.06%] [−5.1, 95% CI {−9.7 to −0.62} mmol/mol]) and weight (−2.9, 95% CI [−4.6 to −1.2] kg); both P < .03. Liraglutide did not change ePFR at rest (−24 ± 60 vs. −6 ± 46 mL/s), during stress (2 ± 58 vs. −2 ± 38 mL/s), or the changes from rest to stress (12.9 ± 72.5 vs. 4.7 ± 104.0; all P > .05). LA PEF decreased with liraglutide during stress (−3.1% [−9.0%, 1.1%] vs. 1.0% [−2.9%, 6.1%]; P = .049), but no changes were evident at rest (−4.3% [−7.9%, 1.9%] vs. −0.6% [−3.1%, 2.2%]; P = .19), or for the changes from rest to stress (−1.7 ± 8.4 vs. 0.8 ± 8.2; P = .4). Secondary outcomes were unchanged by liraglutide. Conclusions Short‐term treatment with liraglutide did not improve left ventricular diastolic function, suggesting the cardioprotective effect is not exerted through the improvement in diastolic dysfunction.
科研通智能强力驱动
Strongly Powered by AbleSci AI